Clinical Trial Update: Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating leuprolide acetate depot (3.75 mg) for prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Leuprolide acetate depot 3.75 mg (leuprolide acetate)

Snippet

Sponsor: GP-Pharm | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED